Medical Cannabis for Ulcerative Colitis: Can Cannabis Help IBD?

What Is Ulcerative Colitis?

• Ulcerative colitis (UC) is a chronic IBD affecting the colon and rectum
• Around 146,000 people in the UK live with UC
• Symptoms include bloody diarrhoea, rectal pain, urgency, and fatigue
• UC follows a relapsing-remitting pattern — flares can last weeks or months
• Treatment escalates from aminosalicylates through biologics to colectomy in severe cases

Ulcerative colitis presents a significant burden on patients’ daily lives. The unpredictable nature of flares, coupled with the side effects of long-term immunosuppression, drives many patients to explore adjunct therapies. Medical cannabis has emerged as one such option, supported by the known role of the endocannabinoid system in gut health.

Cannabis and Colonic Inflammation: What the Research Shows

• The colon contains a high density of CB1 and CB2 receptors
• Endocannabinoids regulate mucosal integrity and inflammatory signalling in the gut
• CBD has shown protective effects on colonic epithelial cells in laboratory studies
• THC may reduce pro-inflammatory cytokine levels in the gut mucosa
• A UCL/Oxford pilot study found cannabis improved UC symptom scores versus placebo

While definitive large-scale trials are still ongoing, the mechanistic and preliminary clinical evidence for cannabis in UC is encouraging. The GW Pharmaceuticals CANNA-UC trial (using CBD) did not reach primary endpoints, but secondary analyses showed meaningful symptom improvements in a subgroup of patients. UK prescribers now use cannabis as part of individualised management plans for patients who have not achieved remission with standard therapies.

Accessing Medical Cannabis for UC in the UK

• UC patients should have documented evidence of failed first and second-line treatments
• A private prescribing clinic will review your gastroenterology records and current symptom burden
• CBD-dominant oils are often the starting point to minimise psychoactive effects
• Some patients benefit from balanced THC:CBD preparations for pain and urgency
• Regular follow-up allows dose titration and monitoring of disease activity markers

UC patients seeking medical cannabis in the UK should approach a licensed clinic with full documentation of their condition, including colonoscopy reports and a list of medications trialled. Prescription cannabis is not available via the NHS for UC — all pathways are currently private. However, costs have fallen considerably as the UK market matures.

Managing Expectations: Benefits and Limitations

• Cannabis is an adjunct, not a replacement for disease-modifying therapies in UC
• Most patients report improvements in pain, urgency, and sleep rather than full remission
• THC-containing products should be used cautiously if mental health co-morbidities are present
• Patients on biologics should inform their gastroenterologist of any new medications, including cannabis
• Some patients reduce corticosteroid reliance with consistent cannabis use under medical supervision

Medical cannabis can offer meaningful quality-of-life improvements for UC patients who have exhausted or are intolerant of standard treatments. The goal is not remission but better symptom control, reduced pain, and improved daily functioning. Honest conversations with both your gastroenterologist and cannabis clinician ensure the safest possible outcome.